Introduction
============

Gastric cancer is one of the most common cancer types worldwide. While its incidence and related mortality is declining, its prevalence is still high, accounting for a major cause of cancer death worldwide including East Asian countries \[[@b1-crt-2015-452],[@b2-crt-2015-452]\].

The prognosis of metastatic or recurrent gastric cancer is generally poor and only palliative chemotherapy was proven to provide a survival benefit \[[@b3-crt-2015-452]\]. Various combination regimens of fluoropyrimidine and platinum with/without trastuzumab, according to the human epidermal growth factor receptor 2 status, are commonly used as the front-line chemotherapy \[[@b4-crt-2015-452]\], and combination regimens were shown to be superior to single-drug regimen in terms of overall survival (OS) \[[@b3-crt-2015-452]\].

In cases of disease progression after the first-line chemotherapy, second-line chemotherapy also appears to provide a survival benefit. Patient survival was significantly prolonged by either docetaxel or irinotecan monotherapy in comparison with best supportive care \[[@b5-crt-2015-452]\]. In addition, in comparison of weekly paclitaxel and irinotecan as a second-line regimen, no difference in terms of survival or tolerability was reported between these two regimens \[[@b6-crt-2015-452]\]. Therefore, taxane or irinotecan monotherapy is currently regarded as two equivalent types of standard second-line chemotherapy. In a recent study, ramucirumab, vascular endothelial growth factor receptor 2 antibody, was shown to provide an additional survival benefit when added to weekly paclitaxel as second-line treatment \[[@b7-crt-2015-452]\].

However, we still do not know whether combination chemotherapy is better than monotherapy in the second-line setting. In fact, combination chemotherapy is still being used in clinical practice. According to a large retrospective study conducted in a single Korean center, out of 725 patients who received second-line chemotherapy, 218 patients were treated with monotherapy, but 507 patients were treated with combination regimen \[[@b8-crt-2015-452]\]. Clinical trials comparing combination chemotherapy with monotherapy in this setting have also been conducted.

A meta-analysis of these trials was conducted to examine the question of whether combination regimens are more effective than monotherapy as a second-line therapy in advanced gastric cancer (AGC).

Materials and Methods
=====================

1. Literature search
--------------------

We searched the MEDLINE and the EMBASE databases and the Cochrane Central Register for Controlled Trials up to 15 July 2015 using guidelines developed for reporting a systematic review \[[@b9-crt-2015-452],[@b10-crt-2015-452]\]. The following keywords were used in the search: "gastric or gastro-esophageal or stomach," "cancer or tumor or malignancy or carcinoma," "chemotherapy," and "second-line or salvage." The titles and abstracts were checked to exclude clearly unrelated articles. All searches were performed independently by the two authors (Y.-H.C and S.Y.Y.).

2. Eligibility criteria
-----------------------

Clinical trials that met the following criteria were included in the meta-analysis: (1) prospective randomized trials; (2) trials comparing a single-drug regimen with a combination regimen as the second-line chemotherapy in AGC patients; (3) trials with available survival data, including progression-free survival (PFS) and OS and hazard ratio (HR) thereby estimated using the 95% confidence interval (CI).

3. Data extraction and quality assessment
-----------------------------------------

Data were extracted from the included studies by two authors (Y.-H.C. and S.Y.Y.). The name of the study or the first author, the year of publication, the study design, the study location, sample size, randomization methods, chemotherapy regimens, follow-up, and survival data were extracted and reviewed. Discrepancies in data extraction were jointly reviewed until a consensus was reached. Study quality was evaluated independently by two authors (Y.-H.C. and S.-N.K.) using the Cochrane Risks of Bias assessment \[[@b11-crt-2015-452]\].

4. Data synthesis and analysis
------------------------------

The primary outcomes of this meta-analysis were pooled HR for OS and PFS for the combination regimen versus monotherapy. For pooled HR analysis, a fixed effects model was used in the absence of significant heterogeneity across the trials. Study heterogeneity was examined by I^2^, which measures the percentage of the total variation across studies and a value greater than 50% defines substantial heterogeneity \[[@b12-crt-2015-452],[@b13-crt-2015-452]\]. When heterogeneity was observed, a random effects model was used to estimate the combined HR. A sensitivity analysis was performed to examine the robustness of conclusions by eliminating each study in the meta-analysis one at a time to determine its effect on the pooled HR. Publication bias was evaluated using the Begg-Mazumdar rank correlation test \[[@b14-crt-2015-452]\], and a funnel plot was constructed for assessment of this bias \[[@b15-crt-2015-452]\]. Statistical tests were performed using Comprehensive Meta-Analysis ver. 2.0 (Biostat, Englewood, NJ), and p \< 0.05 was considered significant.

Results
=======

1. Literature search
--------------------

Initially 1,355 articles were found from three databases using the pre-defined keywords. After excluding 345 duplications, 970 articles were identified, which were then screened by the title or the abstract. Eight articles or abstracts were considered appropriate and were assessed for eligibility; two studies were not randomized trials and one study did not report the HR for survival. Out of the five remaining studies, four studies compared irinotecan monotherapy with combination and the other study used either irinotecan or paclitaxel as monotherapy. Due to the rarity of taxane-based study, we decided to focus only on irinotecan-based studies. Finally, four irinotecan-based studies were included in the meta-analysis ([Fig. 1](#f1-crt-2015-452){ref-type="fig"}).

2. Study characteristics
------------------------

All studies were published relatively recently ([Table 1](#t1-crt-2015-452){ref-type="table"}) \[[@b16-crt-2015-452]-[@b19-crt-2015-452]\]. Two studies evaluated cisplatin as the combination partner to irinotecan and two other studies evaluated fluoropyrimidine (S-1 or 5-fluorouracil \[5-FU\]). Except one study, variable proportions (56%-100%) of patients in the combination therapy group were previously exposed to the partner agents. In particular, one Japanese study evaluated S-1 combination in all S-1--refractory patients \[[@b19-crt-2015-452]\].

While three studies reported no difference in terms of the OS or PFS between two groups, the TCOG GI-0801/BIRIP study reported better PFS, but similar OS in the combination therapy compared with the monotherapy \[[@b17-crt-2015-452]\].

According to the Cochrane Risk of Bias assessment, three trials had "unclear" risk of selection biases because they did not specify randomization methods. Otherwise, there was no additional risk of bias in all trials ([Fig. 2](#f2-crt-2015-452){ref-type="fig"}).

3. Meta-analysis
----------------

A total of 661 patients were included in the meta-analysis; 331 patients were assigned to combination treatment and 330 to monotherapy. The pooled HR for OS and PFS for the combination versus irinotecan monotherapy was 0.938 (95% CI, 0.796 to 1.104; p=0.442) and 0.815 (95% CI, 0.693 to 0.958; p=0.013) ([Figs. 3](#f3-crt-2015-452){ref-type="fig"} and [4](#f4-crt-2015-452){ref-type="fig"}). Thus, a significant risk reduction of progression was observed with combination therapy, although survival was not increased. The fixed model was applied since heterogeneity was not detected across the studies of OS (p=0.911 and I^2^ =0.000) and PFS (p=0.688 and I^2^ =0.000). In the sensitivity analysis, which was performed to examine the robustness of data, no individual study had a significant effect on the pooled HR for both OS and PFS. The funnel plot drawn for the assessment of publication bias showed symmetricity of the studies, and the Begg-Mazumdar rank correlation test also showed no evidence of publication bias in this meta-analysis.

Because it seemed possible that the previous exposure to the partner drug could affect the therapeutic efficacy of combination regimens, a subgroup analysis was performed based on the degree of previous exposure to the chemoagents used in combination. The "full exposure" group (one Japanese study with S-1 combination in all S-1--exposed patients) was compared with the "partial exposure" group (remaining three studies in which up to 56% of patients were previously exposed to the partner drugs). The risk reduction of progression by combination regimen was observed only in the "partial exposure" group (HR, 0.784; 95% CI, 0.628 to 0.980; p=0.032), not in the "full exposure" group (HR, 0.85; 95% CI, 0.673 to 1.074; p=0.174) ([Figs. 5](#f5-crt-2015-452){ref-type="fig"} and [6](#f6-crt-2015-452){ref-type="fig"}).

Discussion
==========

In this meta-analysis, irinotecan-based combination chemotherapy was associated with better PFS, i.e., approximately 18% risk reduction of progression over irinotecan monotherapy. However, this prolonged PFS did not translate to gain of OS, which is not an uncommon observation in cancer chemotherapy trials. The reason for this is not obvious; however, some potential explanations could be offered as follows. First, because the treatment beyond progression was not controlled in these trials, there might have been an imbalance of post-progression therapy between the two arms. Second, due to small sample size, it is also possible that the meta-analysis was underpowered to show a survival difference, despite a PFS benefit. A biological speculation was also proposed that a combination therapy could delay progression for a time but lead to a more aggressive phenotype after treatment, thus offsetting the earlier delay in progression \[[@b20-crt-2015-452]\].

Some patients in the combination arm were treated with previously exposed drugs. Re-administration of a previously exposed drug is not uncommon in cancer chemotherapy. In the case of metastatic colorectal cancer or non-small cell lung cancer, 5-FU/leucovorin or cisplatin is often maintained in the second-line treatment. However, according to the subgroup analysis in this meta-analysis, the degree of previous exposure appears to affect patients' outcome, i.e., only the "partial exposure" group showed a significant risk reduction of progression. Thus, in order to enhance the therapeutic efficacy of second-line therapy, a combination with a new agent might be more desirable. However, due to the limitation of available active agents, use of non-cross-resistant derivatives may be a more realistic alternative. A small phase II trial comparing weekly docetaxel plus oxaliplatin with docetaxel alone in 52 metastatic gastric cancer patients previously treated with cisplatin based regimen \[[@b21-crt-2015-452]\] reported a significant prolongation of PFS (median PFS, 4.93 months vs. 1.97 months; p=0.007) and an equivalent OS (median OS, 8.1 months vs. 7.2 months; p=0.353) in the doublet arm.

Oxaliplatin, a platinum derivative, showed substantial activity in cisplatin-refractory metastatic gastric cancer \[[@b22-crt-2015-452]\]. Newer oral fluoropyrimidines, such as capecitabine and S-1, are currently available, although their cross-resistance with intravenous 5-FU has not been determined. Further studies may be warranted.

A few limitations of this meta-analysis should be noted.

First, the number of patients was relatively small. Except one large Japanese trial, which tested S-1 combination in all S-1 exposed patients, the three remaining studies were even smaller. The small sample size might not have been sufficient to reflect general gastric cancer patients in the second-line setting.

Second, only irinotecan-based studies were included in the meta-analysis. Thus, we still may not be able to make a conclusion regarding taxane-containing combinations in this setting.

Third, details regarding relevant clinical and pathological factors, which might have influenced the patients' outcome, were not available and therefore could not be analyzed. For example, in the above mentioned study by Nishikawa et al. \[[@b18-crt-2015-452]\], irinotecan/cisplatin combination was significantly more effective for intestinal-type AGC, but not for diffuse type.

Conclusion
==========

Second-line irinotecan-based combination chemotherapy was not associated with OS benefit compared to irinotecan monotherapy for AGC. However, it was associated with increased PFS, which seemed particularly significant for patients receiving combination therapy that included a new agent.
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###### 

Characteristics of the studies included in the meta-analysis

  Study                                      Year   Regimen                No.   PFS (mo)   HR_PFS     OS (mo)   HR_OS     Comment
  ------------------------------------------ ------ ---------------------- ----- ---------- ---------- --------- --------- --------------------------
  Sym et al. \[[@b16-crt-2015-452]\]         2013   FOLFIRI                30    3.0        0.83       6.7       0.83      Previous 5-FU (46%)
                                                    Irinotecan             29    2.2        p=0.481    5.8       p=0.514   
  TCOG GI-0801 \[[@b17-crt-2015-452]\]       2014   Irinotecan+cisplatin   64    3.8        0.68       10.7      1.00      Previous cisplatin (56%)
                                                    Irinotecan             66    2.8        p=0.0398   10.1      p=0.982   
  Nishikawa et al. \[[@b18-crt-2015-452]\]   2015   Irinotecan+cisplatin   84    4.6        0.86       13.9      0.834     No previous platinum
                                                    Irinotecan             84    4.1        p=0.376    12.7      p=0.288   
  JACCRO GC-05 \[[@b19-crt-2015-452]\]       2015   Irinotecan+S-1         153   3.8        0.85       8.8       0.99      All S-1 refractory
                                                    Irinotecan             151   3.4        p=0.16     9.5       p=0.92    

PFS, progression-free survival; HR, hazard ratio; OS, overall survival; FOLFIRI, irinotecan plus 5-fluorouracil/leucovorin; 5-FU, 5-fluorouracil.
